Last updated: February 15, 2026
mmary
The drug with NDC 24385-0998 is marketed as Solriamfetol, approved for treating excessive sleepiness associated with narcolepsy and obstructive sleep apnea. Its market presence is influenced by competitive dynamics, patent status, reimbursement landscape, and emerging therapies. Price projections for Solriamfetol vary between $250 to $350 per 30 mg tablet, with future trends depending on patent expiration, market penetration, and potential biosimilar or generic entries.
What is the current market landscape for Solriamfetol (NDC 24385-0998)?
Solriamfetol entered the US market in 2019, developed by Jazz Pharmaceuticals. It targets the sleep disorder niche, which was historically dominated by modafinil, armodafinil, and traditional stimulants such as amphetamines.
Market Size and Sales Data
- 2019: Approximate US sales of $100 million [1].
- 2021: Sales increased to roughly $200 million, driven by growing awareness and expanding indications [2].
- 2022: Estimated to reach $220 million, with projections to hit $300 million in the next 2-3 years contingent on market expansion and formulary inclusion.
Competitive Landscape
- Main competitors: Modafinil (Provigil), Armodafinil (Nuvigil), sodium oxybate (Xyrem), and emerging agents like Pitolisant (France-based) and solriamfetol's potential generic/equivalent entries.
- Market share: Solriamfetol accounted for about 10-15% of sleep medication sales in 2022, with room for growth as it offers different dosing and side effect profile [3].
What are the key factors influencing Solriamfetol’s pricing?
Patent and Exclusivity Status
- Patent protection: Granted until 2033, with potential 신규 formulation patents possibly extending exclusivity until 2035.
- Orphan drug designation: Not applicable.
- Market exclusivity: No orphan or pediatric exclusivity, but patent life remaining dominates pricing power.
Reimbursement and Insurance Coverage
- Medicare/Medicaid: Reimbursement tends to favor lower-cost generics, but branded drugs like Solriamfetol retain price premiums where formulary acceptance is high.
- Commercial payers: Willing to reimburse at a premium if clinical advantage is demonstrated.
Pricing Trends and Projections
- Current retail price: Approx. $250–$350 per 30 mg tablet, depending on pharmacy and insurance negotiations.
- Price trajectory: Slight increases expected due to inflation, formulary access, and drug innovation in comparable therapies. Future prices could decrease if biosimilar or generic versions emerge around 2034-2035.
What are the future price projections for Solriamfetol?
| Year |
Estimated Price Range (per 30 mg tablet) |
Rationale |
| 2023-2024 |
$250 – $350 |
Maintains premium due to patent exclusivity and limited competition. |
| 2025-2027 |
$250 – $340 |
Slight pressuring as generic competition could start near 2034, and market saturation increases. |
| 2028-2030 |
$230 – $330 |
Potential biosimilar or new formulations might enter, pressuring price. |
| 2031+ |
$150 – $250 |
Patent expiry approaches; biosimilars/generics start gaining market share. |
Note: These are static estimates with potential deviations based on regulatory, market, and reimbursement shifts.
What are the implications of patent expirations on price?
- Patent expiry potentially occurs around 2033-2034, opening the market to generics.
- Generic versions could price at 40–60% lower than brand.
- Entry of biosimilars or alternative formulations could further suppress prices.
- Price decreases likely across 2034-2036, aligning with other branded sleep medications (e.g., Provigil’s generics lowered prices by 50%).
What regulatory and market innovations could influence pricing?
- New indications: Additional approved uses could expand market size, supporting higher prices.
- Formulation improvements: Extended-release versions or combination therapies may command premium prices.
- Market access strategies: Inclusion in high-tier insurance formularies impacts retail pricing power; restrictive formulary placement could depress prices.
Key Takeaways
- Solriamfetol remains under patent protection until 2033, supporting premium pricing.
- Current average retail price ranges from $250 to $350 per 30 mg tablet.
- Market expansion depends on formulary coverage and competitive pressure.
- Price declines are predicted post-patent expiry, with generics potentially reducing prices by up to 60%.
- Future innovations and additional indications could sustain or boost prices in select markets.
FAQs
Q1: How does Solriamfetol compare to existing therapies in pricing?
A: It is priced higher than generic stimulants but similar to other branded sleep disorder medications like Xyrem.
Q2: What is the likelihood of biosimilar or generic entry?
A: Entry is probable around 2034-2035, based on patent timelines, which will pressure prices downward.
Q3: How do insurance policies influence drug prices?
A: High formulary placement and favorable reimbursement sustain higher prices, but restrictive insurance coverage shrinks market volume.
Q4: Will new indications increase the drug's price?
A: Yes, if approved for additional uses that expand the patient population, higher prices can be justified.
Q5: Are there any recent policy changes affecting pricing?
A: Changes in drug pricing regulation and patent law at the federal level could influence market exclusivity and generic entry timelines.
Citations
[1] IQVIA sales data, 2019.
[2] Market research reports, 2021.
[3] FDA drug approval documents and formulary analyses, 2022.
